Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

Merck & Co., Inc.

Drugmaker with rare disease work · based in Rahway, United States · founded 1891 · ticker MRK · merck.com

Merck & Co., Inc. works on 23 rare diseases we track, including Acute Myeloid Leukemia, Adrenocortical Carcinoma and 21 more. It has 30 active clinical trials, and 13 are looking for volunteers now. It also has 5 FDA-approved rare disease drugs.

Merck is a global pharmaceutical company with a substantial rare disease presence through oncology and cardiovascular programs. The company's Keytruda franchise covers rare cancers including Merkel cell carcinoma and mesothelioma, while Winrevair (sotatercept) became the first activin signaling inhibitor approved for pulmonary arterial hypertension in 2024.

Merck & Co., Inc. pipeline

Each row lists the diseases Merck & Co., Inc. is studying at that stage, from the ones closest to approval down to the earliest work.

Approved
Drugs the FDA has approved.

Keytruda (pembrolizumab) · Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) · Welireg (belzutifan) · Winrevair (sotatercept-csrk) · Isentress (raltegravir)

Phase 3
Large studies, usually the last step before a company asks the FDA for approval.
Phase 2
Mid-size studies that check whether a drug works and at what dose.

Merkel Cell Carcinoma 2 trials recruiting · Pheochromocytoma recruiting · Non-cystic Fibrosis Bronchiectasis recruiting · Primary Central Nervous System Lymphoma recruiting · Multiple Myeloma recruiting · Desmoid Tumors recruiting · Beta-Thalassemia recruiting · Essential Thrombocythemia 2 trials · Niemann-Pick Disease Type C · Hodgkin Lymphoma · and 6 more

Phase 1
First studies in people, mostly checking safety.

Healthy Participants recruiting · Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma recruiting · Acute Myeloid Leukemia recruiting · Neurofibromatosis Type 1 · Multiple Myeloma

Other studies
Studies with no phase listed, such as registries and natural history studies.

Leukodystrophy recruiting · Multiple Sclerosis · Spinal Muscular Atrophy

Merck & Co., Inc. clinical trials

These are Merck & Co., Inc. trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.

13 trials looking for volunteers now

Looking for volunteersPhase 3Recently updatedNCT06463587

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Tests Placebo, Cladribine Low Dose, Cladribine High Dose

For Generalized Myasthenia Gravis

The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of oral cladribine in gMG. An additional component is included to characterize the Pharmacokinetics (PK) of the new cladribine formulation in gMG participants. This study is divided into 3 periods: the double-blind placebo control (DBPC) pivotal period, and 2 extensions, the blinded extension (BE) and the retreatment (RT) period. Furthermore, in trial interviews will be conducted as a sub-study to MyClad with a sub-set of participants to gain an in depth understanding of the participant cladribine treatment and study experience.

Ages 18 Years+159 locations
View full study
Looking for volunteersPhase 1Recently updatedNCT07300085

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)

Tests Fluzone® High-Dose (HD) influenza vaccine, MK-1406 Injection, Placebo

For Healthy Participants

Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza is currently recommended. However, the real-world vaccine effectiveness varied from 10% to 60% in the general population across the years of 2004 to 2024, with effectiveness in most years below 50% (CDC 2025) and decreasing to as low as 5% in immunocompromised individuals (Hughes 2021). Researchers are looking for other ways to prevent severe illness from the influenza virus. The goals of this study are to learn if: * MK-1406 (formerly CD388) is safe to take with Fluzone® * MK-1406 affects the immune response to Fluzone®

Ages 18 Years - 49 Years15 locations
View full study
Looking for volunteersPhase 2Recently updatedNCT04924075

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Tests Belzutifan

For Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor and HIF-2α Mutated Cancers

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Ages 12 Years+86 locations
View full study
Looking for volunteersRecently updatedNCT03047369

The Myelin Disorders Biorepository Project

For Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome and Adrenoleukodystrophy

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.

Ages not specified24 locations
View full study
Looking for volunteersPhase 3Recently updatedNCT06351631

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Tests Bomedemstat

For Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis and Post-essential Thrombocythemia Myelofibrosis

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic response. No hypothesis testing will be conducted in this study.

Ages 18 Years+21 locations
View full study
Looking for volunteersPhase 1Recently updatedNCT06189391

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

Tests MK-1045

For Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Researchers are looking for new ways to treat people with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). B-cells are a type of white blood cells that make antibodies and help fight infections. Non-Hodgkin Lymphoma is a type of cancer in the lymphatic system causing enlarged lymph nodes and/or organs in belly or chest. Relapsed means a disease or condition comes back after treatment Refractory means a disease does not respond to treatment or stops responding to a treatment. MK-1045, the study medicine, is designed to treat relapsed or refractory B-NHL. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This is the first study in which MK-1045 will be given to people. The goal of this study is to learn about: * The safety of MK-1045 and how well people tolerate it. * The highest dose of MK-1045 that is well tolerated. * How well MK-1045 works to treat relapsed or refractory B-NHL.

Ages 18 Years - 75 Years15 locations
View full study
Looking for volunteersPhase 2Recently updatedNCT06559150

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

Tests Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution

For Non-cystic Fibrosis Bronchiectasis

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer up to 52 weeks, compared to placebo, in participants with non-cystic fibrosis bronchiectasis (NCFBE).

Ages 18 Years - 80 Years51 locations
View full study
Looking for volunteersPhase 1/2Recently updatedNCT04421560

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Tests Ibrutinib, Pembrolizumab, Rituximab

For Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer and Relapsed Cancer

This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: * Pembrolizumab (MK3475) * Ibrutinib * Rituximab (or biosimilar)

Ages 18 Years+4 locations
View full study
Ask about Merck & Co., Inc.'s trials
Answers with sources, in plain English
Start withor ask
Follow a condition Merck & Co., Inc. is studying

Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Merck & Co., Inc.. Unsubscribe anytime.

You'll get, for Acute Myeloid Leukemia:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

FDA-approved drugs from Merck & Co., Inc.

From the openFDA database. Tap a drug for side effects, dosing and help paying.

Keytruda pembrolizumab

For Mesothelioma, Merkel Cell Carcinoma and Hodgkin Lymphoma. Approved Sep 4, 2014. Taken by intravenous route.

Keytruda Qlex pembrolizumab and berahyaluronidase alfa-pmph

For Mesothelioma and Merkel Cell Carcinoma. Approved Sep 19, 2025. Taken by subcutaneous route.

Welireg belzutifan

For Paraganglioma and Pheochromocytoma. Approved Aug 13, 2021.

Winrevair sotatercept-csrk

For Pulmonary Arterial Hypertension. Approved Mar 26, 2024.

Isentress raltegravir

For Huntington Disease. Taken by mouth.

More about Merck & Co., Inc.

Within its broader pharmaceutical portfolio, Merck & Co., Inc. has active clinical trial programs and drug development efforts across 23 rare diseases, including Acute Myeloid Leukemia, Adrenocortical Carcinoma, Cholangiocarcinoma, Essential Thrombocythemia, Gastrointestinal Stromal Tumor, and 18 additional rare conditions. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.

The clinical trials section below shows active and recruiting rare disease studies sponsored by Merck & Co., Inc., sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites.

The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.

Merck & Co., Inc. is headquartered in Rahway, United States, founded in 1891, publicly traded under the ticker symbol MRK. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.

Where Merck & Co., Inc. trials take place

The trials above run at 1,192 study sites in 48 countries. Tap a country to see its states, cities and hospitals.

United States
401▼
Italy
68▼
Spain
61▼
France
54▼
Japan
46▼
China
45▼
Germany
44▼
Australia
41▼
United Kingdom
40▼
Greece
30▼
Poland
29▼
South Korea
28▼

Rare diseases Merck & Co., Inc. works on

Each disease page lists every open trial, not only Merck & Co., Inc.'s, plus approved treatments.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a fast-growing cancer of the bone marrow in which immature white blood cells called blasts crowd out normal blood cells, causing fatigue, infections and bleeding...

How common: The National Cancer Institute's SEER program estimates 22,720 new US cases and 11,500 deaths in 2026, about 1.1% of new cancers, and 83,311 people were living with AML in 2023

Adrenocortical Carcinoma

Adrenocortical carcinoma is a rare, aggressive cancer of the adrenal cortex, the outer layer of the adrenal glands that sit on top of each kidney.

How common: About 1-2 per million people per year; approximately 600 new cases per year in the U.S

Cholangiocarcinoma

Cholangiocarcinoma is a rare and aggressive cancer that forms in the bile ducts, the thin tubes that carry digestive fluid (bile) from the liver to the small intestine.

How common: About 8,000 new cases per year in the U.S.; rising incidence worldwide

Essential Thrombocythemia

Essential Thrombocythemia is a myeloproliferative neoplasm characterized by overproduction of platelets by bone marrow, resulting in very high platelet counts.

How common: About 1 new case per 100,000 people each year, with an estimated 30 to 60 per 100,000 living with it (NORD); average age at diagnosis is in the mid-fifties

Gastrointestinal Stromal Tumor

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, arising from the interstitial cells of Cajal or their precursors.

How common: About 6,000 new cases per year in the U.S. (American Cancer Society); true incidence may be higher as small GISTs are often incidentally discovered

Hodgkin Lymphoma

Hodgkin lymphoma is a cancer of the lymphatic system characterized by the presence of abnormal Reed-Sternberg cells.

How common: About 8,920 new cases expected in the U.S. in 2026 (American Cancer Society); approximately 2.6 per 100,000 people

Mantle Cell Lymphoma

Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma that starts in B cells, a kind of white blood cell.

How common: About 1 in 200,000 people (Cleveland Clinic)

Merkel Cell Carcinoma

Merkel cell carcinoma is a rare, aggressive skin cancer that arises from Merkel cells, specialized touch receptors in the skin.

How common: About 2,500 new U.S. cases in 2013, projected to pass 3,000 a year by 2025; reported cases nearly doubled from 2000 to 2013 (Paulson, 2018)

Mesothelioma

Mesothelioma is a rare, aggressive cancer that develops in the mesothelium, the thin layer of tissue covering most internal organs.

How common: About 3,000 new cases per year in the U.S

Multiple Myeloma

Multiple myeloma is a cancer of plasma cells, the white blood cells that make antibodies.

How common: About 36,000 new US diagnoses expected in 2026 and roughly 203,000 people living with it, which puts myeloma right at the edge of the US rare disease threshold; it is 1.7% of all new cancers (NCI SEER)

Multiple Sclerosis

Multiple sclerosis is a chronic autoimmune disease where the immune system attacks the protective myelin sheath surrounding nerve fibers in the brain and spinal cord.

How common: Approximately 1 million people in the U.S.; about 1 in 300

Myelodysplastic Syndromes

Myelodysplastic syndromes are a group of blood cancers in which the bone marrow fails to produce enough healthy blood cells.

How common: 10,000 to 15,000 new cases annually in the U.S.; estimated 60,000 to 170,000 Americans living with MDS

Myelofibrosis

Myelofibrosis is a myeloproliferative neoplasm in which bone marrow develops scarring (fibrosis), leading to anemia, enlarged spleen, and abnormal blood cell counts.

How common: Approximately 0.5-1.5 cases per 100,000 people; median age of diagnosis is 65 years

Neurofibromatosis Type 1

Neurofibromatosis type 1 is a genetic disorder caused by mutations in the NF1 gene on chromosome 17, which encodes neurofibromin, a tumor suppressor protein.

How common: 1 in 2,500 to 3,500 people in the U.S., making it one of the most common genetic conditions

Paraganglioma

Paragangliomas are rare neuroendocrine tumors arising from chromaffin tissue outside the adrenal medulla.

How common: 1 in 300,000 to 1,000,000; ~30% are hereditary

Pheochromocytoma

Pheochromocytoma is a rare neuroendocrine tumor arising from chromaffin cells of the adrenal medulla that produces excessive catecholamines (epinephrine and norepinephrine).

How common: About 2 to 8 new cases per million people a year (National Cancer Institute)

Polycythemia Vera

Polycythemia Vera is a myeloproliferative neoplasm in which bone marrow produces too many red blood cells, leading to thick blood that carries oxygen less effectively and increases clot risk.

How common: About 44 to 57 per 100,000 people in the US, from 2 large health plans in 2008 to 2010 (Mehta et al., Leukemia and Lymphoma 2014); median age of diagnosis is 65 years

Primary Central Nervous System Lymphoma

Primary central nervous system lymphoma (PCNSL) is a fast-growing lymphoma that starts in the brain, spinal cord, eyes or the membranes around them and usually stays there.

How common: About 5 new cases per million people a year in the US (Ono Pharmaceutical and Deciphera); more than half of patients are 60 or older

Pulmonary Arterial Hypertension

Pulmonary arterial hypertension is a rare disease characterized by abnormally high blood pressure in the pulmonary arteries, causing progressive heart and lung damage.

How common: About 26 to 52 per million people in a Scottish national study, with about 7 new cases per million people each year (Peacock et al., European Respiratory Journal, 2007)

Recurrent Respiratory Papillomatosis

Recurrent respiratory papillomatosis (RRP) is a rare disease in which wart-like growths caused by HPV types 6 and 11 grow in the airway, most often on the voice box.

How common: In the US, CDC estimates put new cases at 2 or fewer per 100,000 children and 2 to 3 per 100,000 adults (NIDCD), and the FDA counts about 1,000 new cases a year

Sarcoidosis

Sarcoidosis is an inflammatory disease characterized by formation of granulomas (clusters of immune cells) in multiple organs, most commonly the lungs and lymph nodes.

How common: An estimated 150,000 to 200,000 people in the United States, about 60 per 100,000, with rates that vary by ethnicity and geography (NORD)

Systemic Sclerosis

Systemic sclerosis (scleroderma) is a rare autoimmune disease in which the immune system triggers scarring (fibrosis) of the skin and internal organs while also damaging small blood vessels.

How common: About 276 per million U.S. adults in a large Detroit-area study; about 19 new cases per million adults each year

Thalassemia

Thalassemia is an inherited blood disorder where reduced or absent production of one type of hemoglobin chain causes anemia, from mild or none in carriers to severe in the major forms, where it can...

How common: About 1 in 100,000 people have symptoms of beta thalassemia, according to NORD, most often people with Mediterranean, Middle Eastern, African or Asian roots

Where to get support

Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Merck & Co., Inc.'s own site is merck.com, and our help paying for treatment page lists drugmaker programs and charity funds.

Questions about Merck & Co., Inc.